4//SEC Filing
Skvarka Jan 4
Accession 0001062993-21-004511
CIK 0001616212other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 4:12 PM ET
Size
17.8 KB
Accession
0001062993-21-004511
Insider Transaction Report
Form 4
Skvarka Jan
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Shares
2021-05-11$0.31/sh+19,198$6,028→ 106,698 total - Exercise/Conversion
Common Shares
2021-05-12$0.31/sh+23,802$7,474→ 23,802 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-05-11−87,500→ 1,162,500 totalExercise: $0.45Exp: 2029-09-25→ Common Shares (87,500 underlying) - Exercise/Conversion
Common Shares
2021-05-11$0.45/sh+87,500$39,043→ 87,500 total - Sale
Common Shares
2021-05-12$9.24/sh−23,802$219,880→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-05-11−19,198→ 220,802 totalExercise: $0.31Exp: 2029-11-07→ Common Shares (19,198 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-05-12−23,802→ 197,000 totalExercise: $0.31Exp: 2029-11-07→ Common Shares (23,802 underlying) - Sale
Common Shares
2021-05-11$9.20/sh−106,698$981,803→ 0 total
Footnotes (5)
- [F1]The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
- [F2]The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.36 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
Issuer
Trillium Therapeutics Inc.
CIK 0001616212
Entity typeother
Related Parties
1- filerCIK 0001838042
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 4:12 PM ET
- Size
- 17.8 KB